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a  b  s  t  r  a  c  t
Radiotherapy (RT) is frequently employed in patients with residual or recurrent pituitary
adenoma with excellent rates of tumor control and remission of hormonal hypersecretion.
Advances in RT have improved with the use of stereotactic techniques either as fractionated
stereotactic radiotherapy (FSRT) or stereotactic radiosurgery (SRS), all aiming to improve
the  dose distribution to the tumor while reducing the amount of normal brain receiving
significant doses of radiation. We  provide an overview of the recent published literature
on the long-term efficacy and adverse effects of stereotactic irradiation in nonfunctioning
and  secreting pituitary adenomas. Both techniques are associated with excellent clinical
outcomes; however, advantages and drawbacks of each of these techniques in terms of local
control, hormonal excess normalization, and radiation-induced toxicity remain a matter
of  debate. In clinical practice, single-fraction SRS may represent a convenient approach to
patients with small and medium-sized pituitary adenoma away at least 2 mm from the opticAcromegaly
Cushing’s disease
chiasm, whereas FSRT is preferred over SRS for lesions >2.5–3 cm in size and/or involving
the  anterior optic pathway.
© 2014 Greater Poland Cancer Centre. Published by Elsevier Urban & Partner Sp. z o.o. All
rights reserved.
Stereotactic techniques have been developed with the aim1.  Background
Radiotherapy (RT) has traditionally been used in patients with
residual or recurrent secreting and nonfunctioning pituitary
adenomas after surgery, resulting in a variable long-term
tumor control of 80–97%1–5 and normalization of elevated hor-
mone levels in 40–70% of patients.6–10 Hypopituitarism occurs
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1507-1367/© 2014 Greater Poland Cancer Centre. Published by Elsevier in 30–60% of patients 5–10 years after irradiation, while other
toxicities, including radiation-induced optic neuropathy, cere-
brovascular accidents, and second tumors have been reported
in 0–3%.10–13pital, University of Rome Sapienza, Via di Grottarossa 1035, 00189
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to deliver more  localized irradiation and minimize the long-
term consequences of treatment. The techniques used for
treatment of pituitary adenomas involve either photon energy
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ith cobalt-60 radiation-emitting sources (Gamma  Knife, GK)
r a modified linear accelerator (LINAC), and are given as a
ingle-fraction stereotactic radiosurgery (SRS) or as fraction-
ted stereotactic radiotherapy (FSRT).14 Data from published
iterature indicate that either SRS or FSRT may achieve excel-
ent long-term tumor control and hormone hypersecretion
ormalization; however, advantages and disadvantages of
he different stereotactic techniques in the management of
atients with pituitary adenomas and their optimal indica-
ions are still a matter of debate.
In this review, we  present an update of the recent avail-
ble literature on the use of stereotactic techniques in
atients with pituitary adenoma. The efficacy, safety, and
ptimal indications for SRS and FSRT in nonfunctioning
nd secreting adenomas, including GH-secreting adenomas,
CTH-secreting adenomas and prolactinomas are discussed.
.  Stereotactic  techniques
tereotactic techniques are a refinement of high conformal
T with further improvement in immobilization, imaging and
reatment delivery. The principal advances of stereotactic
echniques are improved immobilization with either a frame-
ased or a frameless mask stereotactic system that act as a
ducial reference system, leading to a submillimetric accu-
acy in terms of patient movement. Stereotactic irradiation
an be delivered as single-fraction SRS, multi-fraction SRS (2–5
ractions), and as FSRT when a conventional fractionation of
.8–2.0 Gy per fraction is used.
In the multiheaded cobalt unit Gamma  Knife (GK), 201
mall Cobalt sources of gamma  rays are arrayed in a hemi-
phere. A primary collimator aims the radiation emitted by
hese sources to a common focal point. A second external
ollimator helmet, which fits within the primary collima-
or, has an array of removable tungsten collimators (one per
ource) with circular apertures from 4 to 18 mm in size that
re used to create different diameter fields at the focus point.
n the new version of the machine (Gamma  Knife Perfex-
on), the external helmet collimators have been replaced by
 single internal collimation system: the cobatl-60 sources
ove along the collimator body to locations, where 4 mm,
 mm,  and 16 mm apertures have been created. High degree
f conformity for larger non-spherical pituitary adenomas
an be achieved through complex multi-isocenter computer
lanning that defines the optimum combinations of number,
perture and position of the collimators. The dose is typically
rescribed at 50% isodose to obtain the maximum dose at the
enter of each pinpointed target and the prescribed dose at
he target edge. Instead of using an array of cobalt sources,
INAC SRS utilizes X-rays which are derived from colliding
ccelerated electrons with a target metal. Linac FSRT uses
ultiple fixed fields or arcs at each daily session, shaped with
 multileaf collimator (MLC). All fields and arcs conform to the
hape of the tumor allowing a sharp dose gradient between
he target and normal brain tissue. Dose conformity can be
mproved by the use of intensity modulation of the beams,
engths and dynamic collimator optimization of arcs, use of
icro-multileaf collimator, and multiple isocenter.therapy 2 1 ( 2 0 1 6 ) 370–378 371
CyberKnife (Accuray, Sunnyvale, CA) is a relatively new
technological device that combines a mobile linear acceler-
ator mounted on a robotic arm with an image-guided robotic
system.15 The treatment couch also has movements in six
degrees of freedom. It has got 3 translation movements (lon-
gitudinal, lateral and vertical) and 3 rotational movements
(pitch, roll and yaw). Patients are fixed in a thermoplastic
mask and the treatment can be delivered as single-fraction
or multi-fraction SRS. Single isocenters are used for spher-
ical lesions, whereas irregularly shaped lesions are usually
treated with a non-isocentric technique. A variable number of
overlapping beams (up to 200) are delivered non-isocentrically
to the target, resulting in excellent dose coverage to the tar-
get and conformity. The set of beam directions and analysis
of dose distribution are chosen through an inverse planning
process.
The superiority in terms of dose delivery and distri-
bution for each of these techniques remains a matter of
debate. Dose distribution to the target delivered by LINAC-
based SRS is usually more  homogeneous as compared
to CyberKnife and GK SRS, and this may represent an
advantage when treating larger tumors that include radiation-
sensitive brain structures. By contrast, GK and CyberKnife
may achieve a better conformity when irradiating irregularly
shaped targets as compared to LINAC-based SRS. Regardless
of the advantages claimed for each of these radiosurgical
techniques, the reported clinical efficacy and toxicity are sim-
ilar.
In FSRT, the delivered total dose is the same as in conven-
tional RT (45–55 Gy in 25–33 daily fractions over a period of 5–6
weeks). Patients are usually immobilized in a high precision
frameless stereotactic mask fixation system with a reported
accuracy of 1–3 mm.16 The principal aim of FSRT is to deliver
more  localized irradiation as compared with conventional RT,
leading to a reduction of the volume of normal brain tissue
irradiated to high radiation doses, possibly minimizing the
long-term consequences of treatment.
The principal difference between SRS and FSRT is in the
number of fractions. Large single doses of radiation as used
in SRS are more  toxic to normal brain structures than similar
doses given in a fractionated manner, as used in FSRT. A dose-
dependent risk of radiation optic neuropathy exists following
single doses of irradiation. A few retrospective studies have
indicated that the incidence of radiation-induced optic neu-
ropathy is about 2% for single doses of 8–12 Gy, and becomes
>10% for doses of 12–15 Gy to the optic apparatus.17–20 Leav-
itt et al.20 have recently reviewed 222 patients treated with GK
SRS for a benign tumor adjacent to the anterior visual pathway.
The risk of optic neuropathy was 0% for patients receiving a
maximum dose of 8–12 Gy and 10% for those receiving >12 Gy,
respectively, suggesting that small portions of anterior visual
pathway in the range of 0.02–0.04 cm3 may receive doses up
to 12 Gy. The reported tolerance of cranial nerves in the cav-
ernous sinus after single-fraction SRS is 16–18 Gy,17,18 whereas
a maximum dose of 12–13 Gy in a single fraction to the brain-
stem is recommended. By contrast, there is no restriction to
the size of pituitary adenoma suitable for FSRT, since the deliv-
ered doses of 45–55 Gy using a conventional fractionation are
within the tolerance of normal brain structures, including the
optic nerves and chiasm.
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3.  Efficacy  and  toxicity  of  SRS
SRS is frequently used in patients with residual or recur-
rent nonfunctioning pituitary adenoma with a reported tumor
control ranging from 87% to 100% at a variable median follow-
up of 36–90 months (Table 1).21–36 In a large retrospective
multicenter study of 512 patients with nonfunctioning pitu-
itary adenomas treated with SRS at a median dose of 16 Gy
to the tumor margin, Sheehan et al.35 reported an actuarial
tumor control of 95% and 85% at 5 and 10 years, respec-
tively. New or worsened hypopituitarism after SRS occurred
in 21% of patients, and progressive or new onset optic neu-
ropathy occurred in 6.6% of patients. A similar 5-year and
10-year tumor control of 97% and 87% has been reported in
a series of 140 patients with nonfunctioning pituitary ade-
noma treated at the University of Virginia with GK SRS using
a median marginal dose of 18 Gy.32 At a median time of 50
months, hypopituitarism was observed in 30.3% of patients
and new or worsening cranial nerve deficits in 13.7% of
patients. Overall, a weighted average tumor control of 95% at
5 years has been observed in 9 studies including 1054 patients
with a nonfunctioning pituitary adenoma, with an incidence
of hypopituitarism of 23% and a new or worsened neurologi-
cal deficit of 6.5%.24–26,29,31,32,34–36 The dose used for achieving
tumor control is 14–16 Gy, which is lower than that usually
employed for controlling tumor growth in patients with secret-
ing pituitary adenomas.
SRS is commonly used in patients with a GH-secreting
pituitary adenoma failing surgery and/or resistant to med-
ical therapy. Data from 28 studies of SRS using a variable
marginal dose of 18–32 Gy (with a mean of 25 Gy) show a
tumor control and biochemical control of disease in 88–97%
and 35–100% of patients, respectively (Table 2).37,21,38–63 How-
ever, the different criteria used to define GH/IFG1 plasma
levels normalization, the variable follow-up period, the preirr-
adiation GH/IGF-I levels and concomitant medical therapies
make difficult the interpretation of published results and the
Table 1 – Summary of recent published results (2000–2014) on S




Izawa et al., 2000 23 19.5 
Wowra and Stummer, 2002 45 16 
Petrovich et al., 2003 56 15 
Pollock and Carpenter, 2003 33 16 
Losa et al., 2004 56 16.6 
Iwai et al., 2005 34 12.3 
Mingione et al., 2006 100 18.5 
Liscak et al., 2007 140 20 
Pollock et al., 2008 62 16 
Gopalan et al., 2011 48 18.4 
Park et al., 2011 125 13 
Starke et al., 2012 140 18 
Runge et al., 2012 61 13 
Wilson et al., 2012 51 14 
Sheehan et al., 2013 512 16 
Lee et al., 2014 41 12 
NA, not assessed.iotherapy 2 1 ( 2 0 1 6 ) 370–378
real efficacy of SRS. Nevertheless, using stringent criteria of
cure, as defined by suppressed GH levels <1 ng/ml during an
oral glucose tolerance test (OGTT) and normal age-corrected
IGF-I levels, the weighted average biochemical remission rate
reported in 8 studies (including 515 patients) was 48% at 5
years,44–47,49,50,53,59 and normalization of GH/IGF-I levels con-
tinued throughout the follow-up period.
Using similar criteria for defining the cure, Jezkova et al.44
reported biochemical remission rates of 45%, 58%, and 57%
at 3, 5, and 8 years, respectively, in 96 acromegalic patients
with a median time to normalization of 66 months. In another
series of 108 patients with acromegaly treated with GK SRS at
University of Milan San Raffaele, Franzin et al.59 reported an
actuarial biochemical remission rate of 58.3% at 5 years, with
an incidence of hypopituitarism of 7.8%. Similar biochemi-
cal remission rates in the range of 45–60% at 5 years have
been observed in the majority of series,44–47,49,50,59 although
lower rates have been reported in a few studies.39,41,43,45,53
Early reports suggest that the declining of serum GH con-
centration after GK SRS is faster compared with fractionated
RT62,63; however, the rate of serum GH/IGF-I decline observed
in other series is similar to that reported following fractionated
RT.41,45,49,50
SRS data for 465 patients with Cushing’s disease included in
15 studies are shown in Table 3.21,58,61,66–77 At a weighted aver-
age follow-up of 46 months, the median tumor control was
98% and biochemical remission of disease, as measured by
normalization of 24 h urinary free cortisol (UFC) and/or plasma
cortisol concentration, was 64%. In a retrospective series of 96
patients with Cushing’s disease treated by GK SRS at the Uni-
versity of Virginia, Sheehan et al.76 reported a tumor control
and biochemical remission rates of 98% and 70%, respectively,
with a time to normalization of 16.6 months. New or worsened
hypopituitarism occurred in 36% of patients, and progressive
or new onset optic neuropathy occurred in 4.5% of patients.
In a series of 40 patients with Cushing’s disease treated by
GK SRS, at a mean follow-up of 54 months, Castinetti et al.70
reported the biochemical remission of disease in 42.5% of







>6 NA 1 NA
55 93 at 3 years 0 14
36 94 at 3 years 4 NA
43 97 at 5 years 0 41 at 5 years
41 88 at 5 years 0 24
60 93 at 5 years 0 6.5
45 92.2 0 25
60 100 0 2
64 95 at 5 years 0 27
95 83 0 39
62 94 at 5 years 0.8 24
50 97 at 5 years 12.8 30.3
83 98 0 9.8
50 100 at 5 years 0 NA
36 95 at 5 years 6.6 21
48 85 at 10 years 2.4 24.4
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Zhang et al., 2000 68 31 >12 100 40 NA NA
Izawa et al., 2000 29 22.5 >6 93 41 0 0
Pollock et al., 2002 26 20 36 100 47 4 16%
Attanasio et al., 2003 30 20 46 100 23 0 6.3%
Jane et al., 2003 64 15 >18 NA 36 0 28
Castinetti et al., 2005 82 26 49.5* NA 17 1.2 17
Gutt et al., 2005 44 23 22 100 48 NA NA
Kobayashi et al., 2005 67 18.9 63 100 17 11 15
Jezkova et al., 2006 96 35 53.7 100 44 at 5 years 0 27.1
Voges et al., 2006 64 16.5 54.3 97 14 and 33 at 3 and
5 years
1.4  13 and 18 at 3 and
5 years
Pollock et al., 2007 46 20 63 100 11 and 60 at 2 and
5 years
0  33 at 5 years
Vik-Mo et al., 2007 53 26.5 67 100 58 and 86 at 5 and
10 years
3.8  10 at 5 years
Jagannathan et al., 2008 95 22 57 98 53 4 34
Losa et al., 2008 83 21.5 69 97 52 and 85 at 5 and
10 years
0  10 at 10 years
Ronchi et al., 2009 35 20 114 100 46 at 10 years 0 50
Wan et al., 2009 103 28 67 95 37 0 6
Hayashi et al., 2010 25 25 36 100 40 0 0
Iwai et al., 2010 26 20 84 96 17 and 47 at 5 and
10 years
0  8
Castinetti et al., 2009 43 28 96 100 42.0 0 23
Leenstra et al., 2010 31 20 32 100 NA NA 45 at 5 years
Erdur et al., 2011 22 23.8 60 95.2 54.5 0 28.6
Sheehan et al., 2011 130 24 31 93.0 53 2.4 24.4
Sicignano et al., 2012 39 25 60 97.7 54 NA 12.3
Franzin et al., 2012 103 22.5 71 97.3 58.3 at 5 years 0 14
Liu et al., 2012 40 21 72 97.5 47.5 0 40
Zeiler et al., 2013 21 14.2 33* 100 30 3.9 13.2
Yan et al., 2013 22 23 98 95 68.2 0 22.7
Wilson et al., 2013 86 20 66 96 18.6 1.2 19.8
NA, not assessed.











Izawa et al., 2000 12 23 >6 100 17 NA 0
Sheehan et al., 2000 43 16.5 44 100 63 2.5 16
Hoybye et al., 2001 18 NA 180 100 83 0 66
Kobayashi et al., 2002 20 28.7 60 100 35 NA NA
Devin et al., 2004 35 14.7 35 91 49 0 40
Castinetti et al., 2007 40 29.5 54 100 42.5 2.5 15
Jagannathan et al., 2007 90 23 45 96 54 5.5a 22
Pollock et al., 2008 8 20 73 100 87 at 4 years 0 26 at 4 years
Tinnel et al., 2008 12 25 37 83.3 50 0 50
Sicignano et al., 2012 15 23.8 60 97.7 64 NA 12.3
Wein et al., 2012 17 18 23 94.1 58.8 0 11.8
Zeiler et al., 2013 8 24.7 35 100 50 3.9 13.2
Grant et al., 2013 15 35 40.2 100 73 3.2 32
Sheehan et al., 2013 96 16 48 98 70 5 36
Wilson et al., 2014 36 20 66 97 25 0 13.9
NA, not assessed.
a In 5 patients who underwent reirradiation.
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patients, with a mean time to hormone normalization of 22
months. Similar remission rates have been shown by oth-
ers, with a variable time to hormonal normalization of 14–26
months (Table 3). A higher margin radiation dose of 25–30 Gy is
significantly associated with better control of adenoma growth
and biochemical remission.64,65,74 A recurrence rate of up to
20% after an initial remission of disease has been reported
in some series,40,66,76 indicating that a careful follow-up is
mandatory also in patients who  achieve hormonal normal-
ization.
SRS is usually reserved for prolactinomas resistant to med-
ical therapy with dopamine agonists. In a large retrospective
series of 112 patients with a prolactinoma treated with GK
using a median dose of 31 Gy, at a median follow-up of 33
months Pan et al.79 reported hormonal normalization rate of
52%. In another series of 26 patients treated with GK SRS,
Pouratian et al.80 observed a tumor control in 89% and remis-
sion of the disease in 26% of patients, respectively, with an
average time to normalization of 24.5 months. Complica-
tions included new pituitary hormone deficiencies in 28% of
patients and cranial nerve palsy in 7% of patients. Overall, data
for 338 patients reported in 11 studies show tumor control and
normalization of serum prolactin concentration in 99% and
35% of patients at a weighted average follow-up of 42 months,
respectively (Table 4).21,54,55,57,72,78–83 Using a variable dose of
18–34 Gy (with a median of 28 Gy), the reported time to hor-
monal response ranges from 12 months to 66 months, with
better tumor control and biochemical remission rates after
single doses >25–30 Gy.79,80
There are only a few reports on the use of LINAC SRS
in patients with either nonfunctioning or secretary pituitary
adenomas.33,34,45,62,63,69,77 The tumor control, biochemical
remission of disease, and toxicity reported so far are broadly
equivalent to those reported for GK SRS.
The overall rate of serious complications after SRS is low.
The main complication is hypopituitarism, which is reported
in 0–66% of patients, with higher rates in those series with
a longer median follow-up. A lower incidence of hypopi-
tuitarism has been observed when normal pituitary gland
receives a single dose <7.5 Gy.55,57 At doses lower than 10 Gy
to the optic apparatus, the reported rate of radiation-induced
optic neuropathy is 0–4%. Cranial neuropathies and brain
radio necrosis have been reported in 2–6% of patients when
marginal doses >20 Gy are used. The risk to develop a new
tumor after SRS appears to be significantly lower than that
seen following fractionated RT,13 however, the relatively short
length of follow-up of most published series does not allow
any definitive conclusion.
Multi-fraction SRS (2–5 fractions) has been employed in
patients with tumors involving the optic apparatus who are
considered not suitable for SRS.84–87 Using doses of 18–24 Gy
delivered in two to five sessions with CyberKnife, Adler et al.84
reported high rates of tumor control and preservation of visual
function in a small group of patients with pituitary adeno-
mas  within 2 mm of the optic apparatus. In a small study of
nine patients with acromegaly treated to doses of 18–24 Gy in
one to three fractions, at a mean follow up of 25.4 months,
biochemical remission was observed in 4 patients.85 Iwata
et al.86 reported a local control rate of 98% at 3 years in 100
patients with nonfunctioning pituitary adenomas treated withiotherapy 2 1 ( 2 0 1 6 ) 370–378
hypofractionated SRS with CyberKnife using 21–25 Gy in 3–5
fractions. Complications were represented by a grade 2 visual
disorders in one patient and new onset of hypopituitarism in
4 patients. However, the evaluation of radiation tolerance of
the optic chiasm and nerves using hypofractionated sched-
ules was not performed. Thus, the efficacy of hypofractionated
treatment schedules in terms of tumor control and reduced
risk of radiation-related adverse effects as compared to single-
fraction SRS needs to be better elucidated in future studies.
4.  Efficacy  and  toxicity  of  FSRT
FSRT data for 668 patients with nonfunctioning and secret-
ing pituitary adenomas reported in 11 studies are showed
in Table 5.88–95,34,96,97 In a series of 110 patients with either
nonfunctioning or secreting pituitary adenomas treated with
FSRT at a dose of 50.4 Gy delivered in 28 fractions, after a
minimum follow-up of 48 months, the 5-year tumor control
was 99%; hormone hypersecretion normalization occurred in
42% (20/47) of patients with a secreting tumor.91 Kong et al.93
reported the clinical outcomes in 125 patients with pituitary
adenomas (54 secreting adenomas and 71 nonfunctioning
adenomas) who received FSRT at a mean dose of 50.4 Gy in
28 fractions or single-fraction GK SRS with a mean marginal
dose of 25.1 Gy. At a mean follow up of 36.7 months, 2-year
and 4-year overall actuarial progression-free survival rates
and hormone complete remission rates were 99% and 97%,
and 26.2% and 76.3%, respectively. No difference was observed
between the FSRT group and the SRS group, although the
median time to complete biochemical remission was shorter
after SRS. Hypopituitarism developed in 5.7% of patients at 3
years and 27.3% of patients at 5 years. A similar high tumor
control for either nonfunctioning or secreting pituitary ade-
nomas has been observed in most series (Table 5).
Only few data are available on the efficacy of FSRT in
secreting adenomas.89,91,92,94,34 In a series of 25 patients with
acromegaly treated by FSRT with a median total dose of 52 Gy,
Milker-Zabel et al.89 reported normalization of elevated GH
levels in 21 (84%) out of 25 patients at a median follow-up of 26
months. In another series of 34 acromegalic patients treated
by FSRT with a total dose of 54 Gy, at a median follow-up of
30 months, 34% of patients had biochemical normalization of
disease, with 29% of patients who developed a deficit of one
or more  pituitary hormones.94 In a small series of 12 patients
with Cushing disease, Colin et al.91 observed hormone nor-
malization in 9 (75%) out of 12 patients after a median time of
29 months.
Hypopituitarism has been observed in 6–48% (median 15%)
of patients at a weighted average follow-up of 37.6 months
(Table 5). Incidence of permanent optic neuropathy occurred
in 1–5% of patients; however, it has been reported in less than
2% with total doses <50 Gy delivered in fractions of 1.8 Gy. No
other complications, such as brain necrosis, second tumors,
and cerebrovascular disease have been reported; however, the
short follow-up does not allow definitive conclusions about
the potential less toxicity of treatment.
In summary, FSRT is a safe and effective treatment in
controlling tumor growth and normalizing hormone hyper-
secretion in patients with a residual or progressive pituitary
reports of practical oncology and radiotherapy 2 1 ( 2 0 1 6 ) 370–378 375











Landolt et al., 2000 20 25 29 85 25 0 NA
Pan et al., 2000 128 31.2 33 99 41 0 NA
Izawa et al., 2000 15 23.8 >6 100 16 0 NA
Pouratian et al., 2006 23 18.6 48 89 26 7 28
Pollock et al., 2008 11 18 48 100 18 at 4 years 9.1 26 at 4 years
Castinetti et al., 2009 15 28 96 100 46.6 0 21
Jezkova et al., 2009 35 34 75.5 97 37.1 NA NA
Tanaka et al., 2010 22 25 60 100 18 4 42 at 4 years
Leenstra et al., 2010 15 20 63 100 NA NA 41
Sheehan et al., 2011 32 24 31 93 26 2.4 24.4
Liu et al., 2013 22 15 36 86 27.3 13.6 4.5
NA, not assessed.











Milker-Zabel et al., 2001 NFA, SA 68 50.4 38 93 at 5 years 7.5 5
Milker-Zabel et al., 2004 GH 20 52.2 26 100 (92a) 0 3
Paek et al., 2005 NFA, SA 68 50 30 98 at 5 years 3 6
Colin et al., 2005 NFA, SA 110 50.4 48 99 at 5 years 1.8 29 at 4 years
Minniti et al., 2006 NFA, SA 92 45 32 98 at 5 years 1 22
Kong et al., 2007 NFA, SA 66 50.4 36.7 97 0 27.3 at 5 years
Roug et al., 2010 GH 34 54 34 91 (30a) 0 29 at 4 years
Schalin-Jantti et al., 2010 NFA, SA 30 45 64 100 0 40
Wilson et al., 2012 NFA 67 50 60.1 93 at 5 years 1.5 7
Kopp et al., 2013 NFA, SA 37 49.4 57 91.9 5 5





















NFA, nonfunctioning adenoma; SA, secreting adenoma.
a Biochemical remission of disease.
denoma; the advantage of reducing the volume of normal
rain irradiated in terms of the reduction in long-term mor-
idity requires longer follow-up.
.  Conclusions
tereotactic irradiation remains an effective treatment modal-
ty for patients with both nonfunctioning and secreting
ituitary adenomas after unsuccessful surgery and/or resis-
ant to medical therapy. Both SRS and FSRT provide excellent
umor control in the range of 85–95% at 5–10 years, with
ormalization of hormone hypersecretion in more  than 50%
f patients. Hypopituitarism represents the most commonly
eported late complication of treatment, whereas the reported
ncidence of other late effect radiation complications are
ow. A few series suggest that multi-fraction SRS may be
n appropriate treatment in patients with tumors in a close
roximity to the optic apparatus; however, the advantages of
ypofractionated schedules in terms of local control and risk
f radiation-induced toxicity as compared to other stereotactic
echniques need to be better evaluated in future studies.
On the evidence available, no data support the superiority
f SRS over FSRT for the treatment of patients with pituitarytumors. Dose and fractionation are usually chosen on the basis
of the size and position of the pituitary adenoma. In current
clinical practice, single-fraction SRS at doses of 16–25 Gy may
represent a convenient approach to patients with a relatively
small pituitary adenoma away from the optic chiasm, whereas
FSRT is preferred over SRS for lesions >2.5–3 cm in size and/or
involving the anterior optic pathway.
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